Symptom Classification Framework for MDD Treatment Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating major depressive disorder (MDD) with antidepressants lack effective biomarkers and indicators for predicting treatment outcomes, leading to delayed and subjective clinical decision-making, as they rely on insufficient baseline data and extended assessment periods.
Innovation Solution
A method involving symptom measure classification into discrete sets based on severity ranges, integrated with factor graphs and additional patient data like metabolomics and demographics, to predict clinical outcomes and optimize treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If pre-therapy baseline data including social, demographic data and clinical data from questionnaires is used to guide clinical decision-making, then the available information for treatment selection is collected, but the data is insufficient to accurately predict treatment outcomes
Solution Approach 1:
The patent segments the continuous symptom severity data into discrete symptom classes (e.g., mild, moderate, severe) at different time points. This segmentation transforms insufficient continuous data into structured categorical data that can be more effectively analyzed by machine learning models to predict treatment outcomes.
Solution Approach 2:
The patent adds temporal dimension by collecting symptom measures at multiple time points (baseline, week 2, week 4, etc.) rather than relying solely on baseline data. This dimensional expansion provides richer information for predicting treatment response and remission.
2Measurement precision
If extended assessment periods are used to determine treatment effectiveness, then more accurate outcome data is obtained, but clinical decision-making is delayed
Solution Approach 1:
The patent performs preliminary classification of symptom severity at baseline and early follow-up time points to predict treatment outcomes before the full treatment course is complete. This preliminary action enables earlier clinical decision-making while maintaining prediction accuracy through the use of trained machine learning models.
Solution Approach 2:
The system implements feedback loops where symptom measures at intermediate time points are continuously fed into the prediction model to update and refine outcome predictions. This allows for dynamic adjustment of treatment recommendations based on emerging data without waiting for the full assessment period.
3Reliability
If symptom measures are continuously monitored at multiple time points, then symptom progression dynamics are captured, but the complexity of data processing increases
Solution Approach 1:
The patent segments the longitudinal symptom data into discrete time-point measurements and classifies each into symptom classes. This segmentation simplifies the complex continuous data into manageable categorical units that are easier to process and analyze while preserving the temporal progression information.
Solution Approach 2:
The patent transforms the parameter representation from continuous symptom severity scores to discrete symptom classes. This parameter transformation reduces data complexity and makes the data more suitable for machine learning classification algorithms while maintaining the essential information about symptom progression.
Data Source
AI summary
The present disclosure provides methods for accurately predicting the dynamics of symptom response to drugs or other interventions for the treatment of major depressive disorder or other psychological conditions. These methods can allow for a shortening of the time period necessary for the evaluation of a drug or other therapeutic intervention. These predictive methods are based on measured and/or self-reported symptom severity measures at two or more points in time. These measures are then discretized into symptom classes (e.g., low, moderate, severe) and the symptom classes are then applied to the predictive model to predict the progression of symptoms and/or the effectiveness of a drug or other therapeutic intervention. The predictive methods may be augmented by metabolomics data, genomics data, or other objective measures taken from a patient, allowing the use of objective physiological measures to diagnosis and treat psychological conditions heretofore diagnosed and assessed using only subjective, self-reported measures.